Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Posted: Monday, February 22, 2021

Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, talks about why enfortumab vedotin may become a new standard of care for patients with advanced bladder cancer. Although this agent is currently indicated for treatment in the third line after chemotherapy and immunotherapy, the EV-301 study’s head-to-head comparison of enfortumab vedotin with chemotherapy might change the therapeutic landscape.